IDEXX Laboratories Inc (IDXX)vsIllumina Inc (ILMN)
IDXX
IDEXX Laboratories Inc
$504.70
-0.36%
HEALTHCARE · Cap: $40.98B
ILMN
Illumina Inc
$206.45
+2.57%
HEALTHCARE · Cap: $31.87B
Smart Verdict
WallStSmart Research — data-driven comparison
IDEXX Laboratories Inc generates 1% more annual revenue ($4.55B vs $4.49B). IDXX leads profitability with a 25.0% profit margin vs 18.3%. ILMN appears more attractively valued with a PEG of 2.69. IDXX earns a higher WallStSmart Score of 63/100 (C+).
IDXX
Buy63
out of 100
Grade: C+
ILMN
Buy56
out of 100
Grade: C
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-48.7%
Fair Value
$436.26
Current Price
$504.70
$68.44 premium
Margin of Safety
+58.4%
Fair Value
$279.71
Current Price
$206.45
$73.26 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Every $100 of equity generates 71 in profit
Strong operational efficiency at 35.0%
Safe zone — low bankruptcy risk
Keeps 25 of every $100 in revenue as profit
Every $100 of equity generates 29 in profit
Strong operational efficiency at 21.1%
Areas to Watch
Premium valuation, high expectations priced in
Expensive relative to growth rate
Trading at 24.7x book value
Premium valuation, high expectations priced in
Trading at 11.0x book value
Grey zone — moderate risk
Expensive relative to growth rate
Comparative Analysis Report
WallStSmart ResearchBull Case : IDXX
The strongest argument for IDXX centers on Return on Equity, Operating Margin, Altman Z-Score. Profitability is solid with margins at 25.0% and operating margin at 35.0%.
Bull Case : ILMN
The strongest argument for ILMN centers on Return on Equity, Operating Margin. Profitability is solid with margins at 18.3% and operating margin at 21.1%.
Bear Case : IDXX
The primary concerns for IDXX are P/E Ratio, PEG Ratio, Price/Book.
Bear Case : ILMN
The primary concerns for ILMN are P/E Ratio, Price/Book, Altman Z-Score.
Key Dynamics to Monitor
IDXX carries more volatility with a beta of 1.54 — expect wider price swings.
IDXX is growing revenue faster at 9.7% — sustainability is the question.
IDXX generates stronger free cash flow (323M), providing more financial flexibility.
Monitor DIAGNOSTICS & RESEARCH industry trends, competitive dynamics, and regulatory changes.
Bottom Line
IDXX scores higher overall (63/100 vs 56/100), backed by strong 25.0% margins. ILMN offers better value entry with a 58.4% margin of safety. Both earn "Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
IDEXX Laboratories Inc
HEALTHCARE · DIAGNOSTICS & RESEARCH · USA
IDEXX Laboratories, Inc. is an American multinational corporation engaged in the development, manufacture, and distribution of products and services for the companion animal veterinary, livestock and poultry, water testing, and dairy markets.
Illumina Inc
HEALTHCARE · DIAGNOSTICS & RESEARCH · USA
Illumina, Inc. is an American company. Incorporated on April 1, 1998, Illumina develops, manufactures, and markets integrated systems for the analysis of genetic variation and biological function. The company provides a line of products and services that serves the sequencing, genotyping and gene expression, and proteomics markets. Its headquarters are located in San Diego, California.
Visit Website →Compare with Other DIAGNOSTICS & RESEARCH Stocks
Want to dig deeper into these stocks?